Sugammadex
- Generic Name
- Sugammadex
- Brand Names
- Bridion, Sugammadex Adroiq, Sugammadex Amomed, Sugammadex Fresenius Kabi, Sugammadex Mylan, Sugammadex Piramal
- Drug Type
- Small Molecule
- Chemical Formula
- C72H112O48S8
- CAS Number
- 343306-71-8
- Unique Ingredient Identifier
- 361LPM2T56
- Background
Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery. Rocuronium bromide and vecuronium bromide are neuromuscular blocking medications that cause temporary paralysis and are especially useful for general anesthesia, ventilation, or tracheal intubation that patients may require for surgery. Sugammadex provides a new treatment option to reverse the effects of those medications and possibly help patients recover sooner post-surgery. Sugammadex (brand name Bridion) is marketed by Merck Sharp and Dohme, and was approved by the United States FDA on December 15, 2015.
- Indication
Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide or vecuronium bromide in adults and pediatric patients ≥2 years old who are undergoing surgery.
- Associated Conditions
- Neuromuscular blockade caused by vecuronium bromide
Effect of Sugammadex for Reversal of Rocuronium-induced Neuromuscular Block on Perioperative Management of Awake Craniotomy
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- Guangzhou General Hospital of Guangzhou Military Command
- Target Recruit Count
- 40
- Registration Number
- NCT05202899
- Locations
- 🇨🇳
Guangzhou Military Region General Hospital, Department of Anesthesiology, Guangzhou, Guangdong, China
Pharmacokinetics of Sugammadex for the Reversal of Moderate Neuromuscular Blockade in Patients During Renal Transplantation
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Guangzhou General Hospital of Guangzhou Military Command
- Target Recruit Count
- 34
- Registration Number
- NCT05187455
- Locations
- 🇨🇳
Guangdong Hospital of Traditional Chinese Medicine, Guanzhou, Guangdong, China
Residual Paralysis and Reversal With Routine Neostigmine Versus Half-dose Sugammadex and Routine Neostigmine
- Conditions
- Complication of AnesthesiaPostoperative Residual CurarizationSugammadexNeuromuscular BlockadeNeostigmineRocuronium
- Interventions
- First Posted Date
- 2021-10-04
- Last Posted Date
- 2021-10-04
- Lead Sponsor
- Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital
- Target Recruit Count
- 113
- Registration Number
- NCT05066035
Influence of Neostigmine vs. Sugammadex on PORC and PPCs by Ultrasonography
- Conditions
- Postoperative Pulmonary Complications
- Interventions
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2021-09-10
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 414
- Registration Number
- NCT05040490
Diaphragm Ultrasound to Evaluate the Antagonistic Effect of Sugammadex
- Conditions
- Diaphragm UltrasonographyLiver DysfunctionSugammadexRocuronium
- Interventions
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 99
- Registration Number
- NCT05028088
- Locations
- 🇨🇳
Union Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
The Feasibility of Sugammadex for General Anesthesia in Patients Undergoing Kidney and Pancreas Transplantation Surgery
- First Posted Date
- 2021-06-29
- Last Posted Date
- 2021-06-29
- Lead Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Target Recruit Count
- 52
- Registration Number
- NCT04944303
- Locations
- 🇨🇳
The Second Affiliated Hospital,Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
Recovery From dNMB Using Different Sugammadex Doses in Elderly Patients Undergoing Robot-assisted Prostatectomy
- Conditions
- Neuromuscular BlockadeProstate Cancer
- Interventions
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2023-01-25
- Target Recruit Count
- 34
- Registration Number
- NCT04854993
- Locations
- 🇮🇹
Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
PKPD of Rocuronium and Sugammadex Profile in Pediatric Patients
- First Posted Date
- 2021-04-20
- Last Posted Date
- 2021-04-20
- Lead Sponsor
- Poznan University of Medical Sciences
- Target Recruit Count
- 37
- Registration Number
- NCT04851574
- Locations
- 🇵🇱
Alicja Bartkowska-Sniatkowska, Poznan, Grand Poland, Poland
Reversal of Neuromuscular Blockade and Perioperative Arrhythmias
- Conditions
- Neuromuscular Blockade
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- Başakşehir Çam & Sakura City Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT04720573
- Locations
- 🇹🇷
Istanbul Medipol University, Istanbul, Turkey
Effect of Muscle Relaxation Reversal on the Success Rate of Motor Evoked Potential Recording
- Conditions
- SugammadexMotor Evoked Potentials
- Interventions
- Drug: Saline
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Beijing Tiantan Hospital
- Target Recruit Count
- 170
- Registration Number
- NCT04608682
- Locations
- 🇨🇳
Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.